GLP-1 and Health: Beyond Weight Loss in the Ozempic Era

This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss ...
STAT

Is the White House’s deal with pharma on GLP-1 drugs a game changer?

President Trump hailed his deal with pharma companies on GLP-1 drug pricing. The question is how big of a difference the deal ...
Healio

Ultra-long-acting GLP-1 induces weight loss at 28 weeks for adults with obesity

An ultra-long-acting GLP-1 was tied to weight loss of up to 12.5% at 28 weeks among adults with overweight or obesity with no ...
BioSpace

Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers

Pfizer seals the deal with Metsera for $10 billion after Novo Nordisk bowed out; President Donald Trump welcomes executives from Novo and Eli Lilly to the White House to announce that the companies’ ...
The Caledonian-Record

Aptera Motors Announces Effectiveness of S-1 Registration Statement for $75 Million Equity Line ...

Aptera Motors Corp. (NASDAQ: SEV), a solar mobility company focused on developing highly efficient vehicles, today announced that its registration statement on ...

Aptera Motors Announces Effectiveness of S-1 Registration Statement for $75 Million Equity Line of Credit Facility

CARLSBAD, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Aptera Motors Corp. (NASDAQ: SEV), a solar mobility company focused on developing highly efficient vehicles, today announced that its registration ...
TipRanks on MSN

Gilead announces ARTISTRY-1 trial meets primary endpoint

Gilead (GILD) announced topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with ...
Everyday Health on MSN

Retatrutide Is a New GLP-1 Hit. But Is It Legal?

Retatrutide is a powerful experimental weight loss drug that currently lacks FDA approval. Learn how it works, plus the legal and safety risks of buying retatrutide online.